flâneur

Going Up: What's Behind the Growth in IVIG Demand

bstquarterly.com · 2,443 words · saved by 1 readers

N/A

“There is still much to be learned about immunoglobulin therapy, and many more clinical applications may yet emerge.”1 — Stephen Jolles, University Hospital of Wales — Srini Kaveri, French Institute of Health and Medical Research — Jordan Orange, University of Pennsylvania School of Medicine By Keith Berman, MPH, MBA LAUNCHED IN EUROPE in the late 1970s and here in the plasma-based therapeutics. Twenty-five years later, 2015 sales of U.S. in 1981, the first intravenous immune globulin (IVIG)…

saved by

related reading